Yearly Archives: 2013

Need Antibodies for That Luminex Assay? Try These Resources to Find Potential Suppliers and User Reviews

December 20th, 2013 / Stephen Angeloni

Off the Shelf Kits and Reagents for Luminex-Based Proteomic Assays While the Luminex platform can be used for the development of genomic and proteomic assays, most of Luminex’s partners have developed a vast selection of proteomic assays for the analysis of cytokines and other protein or small molecule analytes. These assays require specific combinations of

Continue reading »

How Luminex xMAP® Technology is Changing HIV Drug Resistance Research

December 12th, 2013 / Cassie Bannister

Scanning electromicrograph of an HIV-infected T cell. HIV Infected T cell by NIAID is licensed under Creative Commons License. Human Immunodeficiency Virus (HIV) was first described 30 years ago, and in those 30 years, over 25 million people have died from it, according to the WHO. It continues to be a global challenge, although research and development teams

Continue reading »

Tech Tuesday: We’re ready to go above and beyond for you!

December 10th, 2013 / Gunjot Rana

Luminex is not only known for the assays based on its proprietary xMAP® Technology, but also exceptional customer service. With a long history of innovation, Luminex is a company of firsts. The first IVD cleared cystic fibrosis assay, the first respiratory assay, and now the first gastrointestinal panel for the U.S. The xTAG® GPP (Gastrointestinal

Continue reading »

Multiplex Immunoassay Development for Detection of Organic Pollutants in Fish

December 4th, 2013 / Cassie Bannister

Kelley Hotspring Fish Farm (Tilapia) by USDA NRCS is licensed under Creative Commons License Tilapia farming is a promising solution to the problem of declining fish stocks. As a species, tilapia thrives well in many different environments, and is therefore being increasingly farmed for human consumption in the United States and Europe. Concerns have been raised

Continue reading »

SA-PE: Where Lasers and Algae Meet

November 19th, 2013 / David Polchert

There are two light sources used to collect data from samples in xMAP® Technology based assays. The red light source (laser for Luminex® 100/200™ and LED for MAGPIX®) excites the internal dyes in the microspheres so that they can be classified on the bead map. The green light source excites any reporter bound to the

Continue reading »

Now That You’re Implementing xTAG® GPP, Are You Ready for Training?

November 5th, 2013 / Darren Duncan

To the delight of patients and medical physicians, you’ve opted to implement the FDA Cleared Luminex xTAG® GPP assay. This is a great decision, and now it’s time to prepare for the upcoming implementation efforts including training. A pre-training evaluation call is necessary to help plan for the upcoming visit by a member of the

Continue reading »

Septicemia Highlighted as Most Expensive Condition Treated in U.S.

November 4th, 2013 / Nanosphere, A Luminex Company

A recent report from the Healthcare Cost and Utilization Project (HCUP) listed septicemia as the most expensive condition treated in U.S. hospitals. The HCUP Statistical Brief #160 describes the distribution of costs by expected primary payer and illustrates the conditions responsible for the greatest percentage of each payer’s hospital costs. Primary payers include Medicaid, Medicare, private insurance, and the uninsured.

Continue reading »

Multiplex Technologies More Effective than ELISA for Antibody Detection

October 31st, 2013 / Cassie Bannister

The results of a recent AIDS vaccine trial, RV144, have given researchers a clue about how to successfully inoculate against HIV. The trial took place in Thailand with over 16,000 participants, and concluded that the vaccine lowered the rate of HIV infection by 31% among those vaccinated compared to those who were not. The trial

Continue reading »

New Study in JCM Characterizes the Performance of the Verigene Clostridium difficile Test

October 28th, 2013 / Nanosphere, A Luminex Company

A recent publication by Karen Carroll et al. in the Journal of Clinical Microbiology (JCM) characterized the performance of the Verigene® Clostridium difficile Nucleic Acid Test (CDF) by comparing CDF results versus both direct and enriched toxigenic culture on stool specimens from patients suspected of having C. difficile infection. A total of 1,875 specimens were analyzed in the multi-center study.

Continue reading »

Why Are Most Scientific Presentations Boring?

October 24th, 2013 / Luminex Corporation

Every scientist has had the pleasure of hearing a sleep-inducing, data-laden presentation. While there may be a great point in even the most boring presentation, this point can get lost in the overall dullness of the delivery. No one wants to be the person giving the boring talk, right? So why do many scientific presentations

Continue reading »